Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dexcom (DXCM) Capital Expenditures (2016 - 2025)

Dexcom (DXCM) has disclosed Capital Expenditures for 16 consecutive years, with $101.9 million as the latest value for Q4 2025.

  • On a quarterly basis, Capital Expenditures fell 18.22% to $101.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was $363.5 million, a 1.31% increase, with the full-year FY2025 number at $363.5 million, up 1.31% from a year prior.
  • Capital Expenditures was $101.9 million for Q4 2025 at Dexcom, up from $80.5 million in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $124.6 million in Q4 2024 to a low of $50.4 million in Q3 2023.
  • A 5-year average of $85.6 million and a median of $89.2 million in 2022 define the central range for Capital Expenditures.
  • Peak YoY movement for Capital Expenditures: soared 200.3% in 2021, then plummeted 53.42% in 2023.
  • Dexcom's Capital Expenditures stood at $80.2 million in 2021, then fell by 20.82% to $63.5 million in 2022, then fell by 17.32% to $52.5 million in 2023, then skyrocketed by 137.33% to $124.6 million in 2024, then decreased by 18.22% to $101.9 million in 2025.
  • Per Business Quant, the three most recent readings for DXCM's Capital Expenditures are $101.9 million (Q4 2025), $80.5 million (Q3 2025), and $94.1 million (Q2 2025).